Gene that may hold key cancer treatment identified

Scientists have identified a gene that plays a critical role in regulating the body's immune response to infection and disease, and may lead to the development of new treatments for influenza, arthritis and even cancer.

The gene, called C6orf106 or "C6", controls the production of proteins involved in infectious diseases, cancer and diabetes. The gene has existed for 500 million years, but its potential is only now understood.

"Our immune system produces proteins called cytokines that help fortify the immune system and work to prevent viruses and other pathogens from replicating and causing disease," said Cameron Stewart, a researcher at Commonwealth Scientific and Industrial Research Organisation (CSIRO) in Australia.

"C6 regulates this process by switching off the production of certain cytokines to stop our immune response from spiralling out of control," Stewart said.

"The cytokines regulated by C6 are implicated in a variety of diseases including cancer, diabetes and inflammatory disorders such as rheumatoid arthritis," he said.

The study published in the Journal of Biological Chemistry, helps improve our understanding of our immune system, and it is hoped that this understanding will enable scientists to develop new, more targeted therapies.

"Even though the human genome was first fully sequenced in 2003, there are still thousands of genes that we know very little about," said Rebecca Ambrose, a former CSIRO researcher, who is now based at the Hudson Institute of Medical Research.

"It's exciting to consider that C6 has existed for more than 500 million years, preserved and passed down from simple organisms all the way to humans. But only now are we gaining insights into its importance," Ambrose said.

Having discovered the function of C6, the researchers are awarded the privilege of naming it, and are enlisting the help of the community to do so.

"The current name, C6orf106, reflects the gene's location within the human genome, rather than relating to any particular function," Stewart said.

"We think we can do better than that, and are inviting suggestions from the public," he said.